InvestorsHub Logo
Followers 9
Posts 675
Boards Moderated 0
Alias Born 09/24/2016

Re: None

Sunday, 02/21/2021 8:26:33 AM

Sunday, February 21, 2021 8:26:33 AM

Post# of 3504
The exchange formula provides that the total number of shares of Cleveland BioLabs’ common stock to be issued as merger consideration for the Cytocom’s capital stock will, upon issuance, be equal to approximately 61% of the outstanding shares of the combined company’s common stock. Accordingly, under the exchange ratio formula in the Merger Agreement, as of immediately after the Merger, the former Cytocom stockholders are expected to own approximately 61% of the outstanding shares of the combined company’s common stock on a fully diluted basis and stockholders of Cleveland BioLabs as of immediately after to the Merger are expected to own approximately 39% of the outstanding shares of the combined company’s common stock on a fully diluted basis https://www.otcmarkets.com/filing/html?id=14707243&guid=8D-aU60g_C90dyh Also IMUN stock .0265 cents owns 15.57% of the common shares issued and outstanding of Cytocom’s stock. date.https://www.sec.gov/Archives/edgar/data/1559356/000149315219017950/form10-q.htm